Primary Peritoneal Carcinoma
Information
- Disease name
- Primary Peritoneal Carcinoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05200364 | Active, not recruiting | Phase 1 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | March 22, 2022 | January 2026 |
| NCT03363867 | Active, not recruiting | Phase 2 | BEACON - ABC in Recurrent Platinum Resistant HGSOC | July 10, 2018 | June 30, 2025 |
| NCT03891576 | Active, not recruiting | Phase 2 | Newton Study (NEW Dosing mainTenance Therapy Ovarian caNcer) | November 13, 2019 | December 31, 2024 |
| NCT03355976 | Active, not recruiting | Phase 2 | BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas | April 30, 2018 | December 2025 |
| NCT04257045 | Active, not recruiting | Factors Influencing Cascade Testing Among Women With Hereditary Gynecological Cancers and Their Relatives | August 21, 2019 | April 30, 2024 | |
| NCT02345265 | Active, not recruiting | Phase 2 | Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer | May 23, 2016 | August 9, 2024 |
| NCT06274541 | Active, not recruiting | Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study | March 22, 2019 | November 2025 | |
| NCT03029403 | Active, not recruiting | Phase 2 | Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer | February 12, 2018 | February 12, 2025 |
| NCT03748186 | Active, not recruiting | Phase 1 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | February 1, 2019 | November 2024 |
| NCT05199272 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies | December 29, 2021 | March 2025 |
| NCT02124421 | Active, not recruiting | Phase 2 | HOT: HIPEC in Ovarian Cancer as Initial Treatment | April 2014 | April 2028 |
| NCT04201561 | Active, not recruiting | Phase 3 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy | December 24, 2019 | December 31, 2024 |
| NCT05483933 | Active, not recruiting | Phase 1 | Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers | August 18, 2022 | April 2025 |
| NCT02584478 | Active, not recruiting | Phase 3 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) | December 2015 | December 2024 |
| NCT04204811 | Active, not recruiting | Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy | December 16, 2019 | December 16, 2024 | |
| NCT02419495 | Active, not recruiting | Phase 1 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | June 26, 2015 | December 31, 2024 |
| NCT01031381 | Completed | Phase 2 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | September 2010 | December 2014 |
| NCT01091259 | Completed | Phase 2 | Irinotecan and Bevacizumab for Recurrent Ovarian Cancer | March 2010 | May 2015 |
| NCT01097746 | Completed | Phase 2 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | April 14, 2010 | September 13, 2022 |
| NCT01118052 | Completed | Phase 2 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | November 1, 2010 | July 16, 2016 |
| NCT01139957 | Completed | Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer | June 7, 2010 | April 10, 2020 | |
| NCT00054119 | Completed | Phase 2 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | January 2003 | |
| NCT01295489 | Completed | Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | March 2011 | ||
| NCT01308944 | Completed | Phase 1 | Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients | August 2010 | August 2015 |
| NCT01381861 | Completed | Phase 2 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | July 2011 | December 2013 |
| NCT01442051 | Completed | N/A | Acute Normovolemic Hemodilution in Patients Undergoing Cytoreductive Surgery for Advanced Ovarian Cancer | September 23, 2011 | July 1, 2019 |
| NCT01506856 | Completed | Phase 2/Phase 3 | Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial | May 2010 | February 28, 2021 |
| NCT01519869 | Completed | Phase 2 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | March 2012 | October 11, 2019 |
| NCT00060359 | Completed | Phase 1 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | April 2003 | |
| NCT01588522 | Completed | Phase 1 | Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease | July 2012 | March 2017 |
| NCT01669226 | Completed | Phase 2 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer | April 2009 | July 2016 |
| NCT01709487 | Completed | Phase 1/Phase 2 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | May 2010 | October 2015 |
| NCT00066456 | Completed | Phase 1 | Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer | September 2003 | |
| NCT00072566 | Completed | Phase 2 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | December 2003 | November 2008 |
| NCT01974765 | Completed | Phase 2 | Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies | November 5, 2013 | February 28, 2022 |
| NCT03921658 | Completed | The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer | October 22, 2019 | April 2, 2024 | |
| NCT04088786 | Completed | Phase 1 | Phase I Trial HIPEC With Nal-irinotecan | October 22, 2019 | April 14, 2022 |
| NCT04406623 | Completed | Phase 1 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | June 29, 2020 | February 2, 2023 |
| NCT04440943 | Completed | Phase 1 | A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies | August 4, 2020 | April 6, 2023 |
| NCT00407563 | Completed | Phase 2 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | January 2007 | February 2011 |
| NCT00478452 | Completed | Phase 1 | Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients | August 2005 | August 2008 |
| NCT00499252 | Completed | Phase 2 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | June 2007 | |
| NCT00511992 | Completed | Phase 2 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | July 2007 | August 3, 2015 |
| NCT00551070 | Completed | Phase 2 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | December 17, 2007 | November 13, 2020 |
| NCT00561795 | Completed | Phase 2 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | September 2007 | April 2008 |
| NCT00045682 | Completed | Phase 2 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | September 2002 | |
| NCT00721162 | Completed | Phase 2 | Study of Ramucirumab in Ovarian Cancer | August 2008 | August 2015 |
| NCT00814086 | Completed | Phase 1 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | February 2009 | |
| NCT00868192 | Completed | Phase 2 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | May 2008 | December 2012 |
| NCT00939809 | Completed | Phase 2 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | July 2009 | |
| NCT00989651 | Completed | Phase 1 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | October 28, 2009 | April 10, 2020 |
| NCT02118285 | Completed | Phase 1 | Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | July 28, 2014 | November 12, 2015 |
| NCT02166905 | Completed | Phase 1/Phase 2 | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | October 10, 2014 | August 20, 2020 |
| NCT02217956 | Completed | Phase 1 | Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma | June 2011 | June 2015 |
| NCT02315469 | Completed | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | February 10, 2015 | February 9, 2019 | |
| NCT00083928 | Completed | Phase 2 | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | May 2004 | December 2006 |
| NCT02578888 | Completed | N/A | Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies | April 2015 | April 2019 |
| NCT02631876 | Completed | Phase 3 | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer | March 2, 2016 | January 2020 |
| NCT00093626 | Completed | Phase 2 | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | October 2004 | January 2011 |
| NCT02725489 | Completed | Phase 2 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | June 3, 2016 | December 2, 2020 |
| NCT02788708 | Completed | Phase 1 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | May 27, 2016 | March 31, 2022 |
| NCT03297489 | Completed | Early Phase 1 | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer | November 6, 2017 | February 15, 2021 |
| NCT00214058 | Completed | Phase 2 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | August 2002 | February 2006 |
| NCT03367260 | Completed | The Treatment Preferences of Women Diagnosed With Ovarian Cancer | October 19, 2017 | January 4, 2019 | |
| NCT00301756 | Completed | Phase 2 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | September 2006 | December 2012 |
| NCT03602079 | Completed | Phase 1/Phase 2 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | July 16, 2018 | January 12, 2022 |
| NCT03604653 | Completed | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | May 15, 2018 | May 1, 2021 | |
| NCT00011986 | Completed | Phase 3 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | January 2001 | January 28, 2013 |
| NCT03783949 | Completed | Phase 2 | European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer | November 30, 2018 | September 1, 2023 |
| NCT00352300 | Completed | Phase 1 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | June 2006 | |
| NCT03849469 | Completed | Phase 1 | A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | May 29, 2019 | February 16, 2023 |
| NCT01445275 | Not yet recruiting | Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199 | January 2100 | ||
| NCT05236686 | Not yet recruiting | N/A | Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian Cancer | February 2022 | December 2025 |
| NCT05200260 | Not yet recruiting | Phase 2 | Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer | February 2022 | February 2027 |
| NCT05043402 | Not yet recruiting | Phase 3 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | November 30, 2022 | August 15, 2024 |
| NCT04515602 | Not yet recruiting | Phase 3 | Stratified Evaluation of PDS and NACT-IDS in Ovarian Cancer (FOCUS) | January 2021 | January 2028 |
| NCT06161272 | Not yet recruiting | Phase 2 | Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi | December 10, 2023 | January 10, 2026 |
| NCT05460000 | Not yet recruiting | Phase 2 | A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy | June 1, 2024 | May 1, 2032 |
| NCT04834544 | Recruiting | Phase 2 | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care | April 19, 2021 | April 20, 2027 |
| NCT04575961 | Recruiting | Phase 2 | Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer | February 22, 2022 | November 1, 2026 |
| NCT05579366 | Recruiting | Phase 1/Phase 2 | PRO1184 for Advanced Solid Tumors | December 7, 2022 | April 2026 |
| NCT00488878 | Recruiting | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors | May 19, 2006 | May 1, 2035 | |
| NCT06084416 | Recruiting | Phase 1 | A Study of Sovilnesib in Subjects With Ovarian Cancer | April 4, 2024 | July 2025 |
| NCT05198804 | Recruiting | Phase 1/Phase 2 | A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | January 27, 2022 | November 2023 |
| NCT05527184 | Recruiting | Phase 1 | First in Human Study of IMGN151 in Recurrent Endometrial Cancer and Recurrent, High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | January 11, 2023 | December 30, 2025 |
| NCT03540017 | Recruiting | Phase 1 | HIPEC After Initial CRS in Patients Who Have Received NACT | March 12, 2019 | July 5, 2025 |
| NCT04375956 | Recruiting | Phase 2 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients | April 26, 2021 | June 15, 2025 |
| NCT03604315 | Recruiting | Phase 1 | Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF | December 18, 2018 | June 30, 2027 |
| NCT06420973 | Recruiting | Phase 2 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | May 16, 2024 | September 17, 2027 |
| NCT05537844 | Recruiting | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma | October 27, 2021 | April 27, 2025 | |
| NCT03150121 | Recruiting | N/A | Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage | June 29, 2014 | December 31, 2024 |
| NCT05446298 | Recruiting | Phase 2 | ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer | December 22, 2022 | June 30, 2026 |
| NCT05429970 | Recruiting | N/A | A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) | June 17, 2022 | June 17, 2025 |
| NCT05788484 | Recruiting | Phase 1 | A Study of CDX-585 in Patients With Advanced Malignancies | May 11, 2023 | February 2026 |
| NCT03983226 | Recruiting | Phase 2 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | October 18, 2019 | December 2026 |
| NCT05858736 | Recruiting | Phase 1 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors | July 11, 2023 | June 15, 2025 |
| NCT01972516 | Terminated | Phase 2 | Tivozanib As Maintenance Therapy In GYN | November 2013 | January 2016 |
| NCT00322881 | Terminated | Phase 2 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | April 2006 | April 2010 |
| NCT00582205 | Terminated | Phase 2 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | January 2006 | December 2011 |
| NCT01202890 | Terminated | Phase 1 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | September 2010 | May 2012 |
| NCT01535157 | Terminated | Phase 1/Phase 2 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | February 2012 | June 2017 |
| NCT01952249 | Terminated | Phase 1 | A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian | August 5, 2013 | July 12, 2016 |
| NCT00004221 | Terminated | Phase 2 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | November 1999 | |
| NCT02485990 | Terminated | Phase 1 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | January 8, 2016 | March 5, 2020 |
| NCT02661815 | Terminated | Phase 1 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | June 15, 2016 | July 28, 2017 |
| NCT03312114 | Terminated | Phase 2 | Anti-PD-L1 and SAbR for Ovarian Cancer | November 9, 2017 | March 19, 2019 |
| NCT03585764 | Terminated | Phase 1 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | October 24, 2018 | March 26, 2024 |
| NCT03608618 | Terminated | Phase 1 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | August 27, 2018 | August 24, 2021 |
| NCT03824704 | Terminated | Phase 2 | A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | August 23, 2019 | August 24, 2020 |
| NCT04814875 | Terminated | Phase 1/Phase 2 | A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy | September 1, 2021 | November 30, 2023 |
| NCT05261490 | Terminated | Phase 1/Phase 2 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer | August 1, 2022 | February 15, 2024 |
| NCT05538624 | Terminated | Phase 1/Phase 2 | A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary | December 9, 2022 | April 10, 2024 |
| NCT04229615 | Unknown status | Phase 3 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | June 2, 2020 | April 1, 2024 |
| NCT02033616 | Unknown status | Phase 2 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | November 18, 2017 | March 2023 |
| NCT01611766 | Unknown status | Phase 3 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | July 19, 2012 | December 2022 |
| NCT01180504 | Unknown status | Phase 2 | Consolidation Whole Abdominal Intensity-Modulated Radiation Therapy (IMRT) in Advanced Ovarian Cancer | August 2010 | August 2016 |
| NCT03648489 | Unknown status | Phase 2 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) | September 21, 2018 | December 2022 |
| NCT03373058 | Unknown status | Phase 3 | Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery | October 15, 2019 | July 1, 2023 |
| NCT03283943 | Unknown status | Phase 1 | PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. | April 1, 2018 | December 16, 2020 |
| NCT00958698 | Unknown status | N/A | Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | January 19, 2010 | |
| NCT03180177 | Unknown status | Phase 3 | Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer | March 1, 2018 | July 1, 2022 |
| NCT03150992 | Unknown status | N/A | EDMONd - Elemental Diet in Bowel Obstruction | July 19, 2017 | December 2019 |
| NCT03000192 | Unknown status | HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life | August 2016 | September 2021 | |
| NCT02859038 | Unknown status | Phase 3 | Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY) | August 2016 | June 2023 |
| NCT02595021 | Unknown status | Phase 2 | Total/Subtotal Colectomy in Ovarian Cancer | July 2015 | December 2018 |
| NCT02344095 | Unknown status | Phase 1 | A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer | December 2014 | October 2015 |
| NCT02328716 | Unknown status | Phase 3 | Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma | February 2012 | December 2018 |
| NCT03607955 | Withdrawn | Phase 1 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | June 30, 2021 | August 31, 2029 |
| NCT00551265 | Withdrawn | N/A | Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy | October 2007 | |
| NCT01138137 | Withdrawn | Phase 1 | N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer | June 2010 | December 2014 |
| NCT04368130 | Withdrawn | N/A | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care | September 1, 2022 | September 1, 2023 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030406
- OrphaNumber from OrphaNet (Orphanet)
- 168829